The curious case of undervalued Indian biotech startups - Economic Times

Though that was a positive development, the total valuation of the 325 startups that C-CAMP backs is only Rs 6,000 crore, or less than $1 billion at current exchange rates. Of these, nearly 100 startups are less than two years old. (Illustration: Rahul Awasthi/ETtech)

Synopsis

Investors have largely been risk-averse when it comes to deep-funding biotech startups that have the potential to turn into billion-dollar entities. Why are they shying away from this space?

Are Indian biotechnology startups undervalued?

There are about 5,000 biotech companies in the country, of which more than 4,000 are startups. While Bengaluru-based Biocon Biologics and Syngene are valued at $1 billion or more – known in startup industry parlance as unicorns – other biotech startups have yet to get there.

Recently, seven deep-tech startups at the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru raised about $70

ETtech

Sep 18, 2022, 06:00 AM IST

FONT SIZE

AbcSmall

AbcMedium

AbcLarge
SAVE
PRINT
COMMENT

Why ?

Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

Stock analysis. Market Research. Industry Trends on 4000+ Stocks

Clean experience with
Minimal Ads

Comment & Engage with ET Prime community

Exclusive invites to Virtual Events with Industry Leaders

A trusted team of Journalists & Analysts who can best filter signal from noise